• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Aloha to New Delgocitinib and Tralokinumab Data

News
Article

Ten posters at the Winter Clinical Hawaii and Maui Derm Conferences will showcase investigational data to expand treatment options for patients with atopic dermatitis and chronic hand eczema.

JHVEPhoto/AdobeStock

JHVEPhoto/AdobeStock

LEO Pharma is set to make waves at the 2024 Winter Clinical Hawaii and Maui Derm Conferences with a comprehensive showcase of clinical and real-world data. Investigators including Andrew Blauvelt, MD, MBA; Peter Lio, MD; and Amy Paller, MD, will be presenting findings on delgocitinib cream and tralokinumab-ldrm (Adbry) across 10 posters, offering an invaluable insight into the treatment landscape for chronic hand eczema (CHE) and atopic dermatitis (AD).1

Investigational Delgocitinib Cream Data

A significant portion of presentations will focus on investigational delgocitinib cream, a topical pan-Janus kinase (JAK) inhibitor currently in development for the treatment of moderate-to-severe chronic hand eczema in adults. The data will include a pooled analysis of the DELTA 1 (NCT04871711)and DELTA 2 (NCT04872101) phase 3 clinical trials, assessing the impact of delgocitinib cream on health-related quality of life through the Dermatology Life Quality Index (DLQI) in patients with moderate to severe CHE.

The 5 posters on delgocitinib cream will cover various aspects, including efficacy and safety in adults, patient-reported outcomes related to itch and pain, and systemic exposure in the phase 3 DELTA 2 trial.

Here are delgocitinib posters and presenters to look out for on the conference floor:

  • Effect of delgocitinib cream 20 mg/g on Dermatology Life Quality Index in patients with moderate-to-severe Chronic Hand Eczema: pooled data from the DELTA 1 and DELTA 2 phase 3 trials. 
    • Author: Marie Louise Schuttelaar 
  • Efficacy and safety of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema: results of the Phase 3 DELTA 2 trial. 
    • Author: Sibylle Schliemann 
  • Efficacy and safety of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema: results of the Phase 3 DELTA 1 trial. 
    • Author: Robert Bissonnette 
  • Patient-reported itch and pain are correlated with clinician-assessed outcomes in Chronic Hand Eczema (CHE). 
    • Author: Tove Agner 
  • Systemic exposure of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema in the phase 3 DELTA 2 trial. 
    • Author: Diamant Thaçi 

Tralokinumab Data Presentations

The other 5 posters will highlight tralokinumab-ldrm, a high-affinity human monoclonal antibody designed to inhibit the interleukin (IL)-13 cytokine, approved for the treatment of moderate-to-severe AD. Posters will specifically focus on both clinical and real-world results in adult and pediatric patients with moderate-to-severe AD. Noteworthy is a 6-month interim analysis of a real-world study in adult patients living in the US, exploring patient-reported quality of life outcomes related to itch, sleep, and treatment satisfaction. 

Here are tralokinumab posters and presenters to look out for on the conference floor:

  • Tralokinumab real-world patient-reported outcomes in moderate-to-severe atopic dermatitis adult patients in the United States: 6-month interim analysis. 
    • Author: Peter Lio 
  • Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities. 
    • Author: Amy Paller
  • Progressive and sustained disease control in patients with atopic dermatitis (AD) aged 12-17 years treated with tralokinumab for 52 weeks. 
    • Author: Andreas Wollenberg 
  • Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control. 
    • Author: Andrew Blauvelt 
  • Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials. 
    • Author: Kristian Reich

Connect With Us

Are you attending the 2024 Winter Clinical Hawaii or Maui Derm Conferences this month? We would love to talk to you and hear your insight on top pearls and takeaways you plan to put into practice! Email us at DTEditor@mmhgroup.com.

Reference

1. LEO Pharma presents data at 2024 Winter Clinical and Maui Derm Conferences. News Release. BioSpace. January 12, 2024. Accessed January 12, 2024. https://www.biospace.com/article/releases/leo-pharma-presents-data-at-2024-winter-clinical-and-maui-derm-conferences/

Related Videos
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
This series features 1 KOL.
This series features 1 KOL.
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Video 5 - featuring 2 panelists in, "Quality of Life + Closing Thoughts
© 2024 MJH Life Sciences

All rights reserved.